Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VTRS
Strong BuySecond WindFLAGViatris Inc. · Healthcare · United States · $18.8B · Avg Vol: $152M/d
Viatris is cheap at V68 with strong momentum M75 and a buyback retiring 1.60% of shares, but quality at Q42 is below the calibrated floor, so stage one fails. The insider selling rounds to 0.00% and is unusable.
COMPANY DESCRIPTION
Viatris Inc. is a global healthcare company formed through the combination of Mylan and Upjohn, specializing in the development, manufacture, and sale of branded, generic, and biosimilar medicines. Its competitive moat is derived from a highly diversified product portfolio, global manufacturing and supply chain capabilities, and broad geographic reach across over 165 countries. Viatris operates as a major global pharmaceutical player, providing access to essential medicines and addressing unmet patient needs worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.3B | 15.4B | 14.7B | 14.3B | -4.2% | 14.7B | 14.8B | 15.0B | 2.5% |
| EPS | 1.71 | 0.05 | -0.53 | -3.00 | -97.1% | -0.37 | — | — | — |
| Shares | 1.2B | 1.2B | 1.2B | 1.2B | -5.2% | 1.1B | — | — | — |
| Debt | 19.5B | 18.4B | 14.3B | 14.7B | -9.0% | 13.6B | — | — | — |
| Equity | 21.1B | 20.5B | 18.6B | 14.7B | -11.3% | — | — | — | — |
| Op CF | 3.0B | 2.9B | 2.3B | 2.3B | -8.3% | 2.3B | — | — | — |
| Inv CF | 1.5B | -864.5M | 1.8B | -427.7M | — | — | — | — | — |
| Fin CF | -3.9B | -2.3B | -4.3B | -1.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VTRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VTRS | Viatris Inc.(you) | $18.8B | 86 | Strong Buy |
| UTHR | United Therapeutics Corporation | $22.1B | 85 | Strong Buy |
| NBIX | Neurocrine Biosciences, Inc. | $15.7B | 85 | Strong Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 88 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 70 | Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
| ZTS | Zoetis Inc. | $32.0B | 66 | Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| LQDA | Liquidia Corporation | $6.1B | 64 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%